L
Linda Henry
Researcher at Stanford University
Publications - 244
Citations - 19660
Linda Henry is an academic researcher from Stanford University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 42, co-authored 197 publications receiving 12359 citations. Previous affiliations of Linda Henry include Inova Health System & University of Florida.
Papers
More filters
Journal ArticleDOI
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
Zobair M. Younossi,Zobair M. Younossi,Aaron B. Koenig,Dinan Abdelatif,Yousef Fazel,Linda Henry,Mark Wymer,Mark Wymer +7 more
TL;DR: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous, and random‐effects models were used to provide point estimates of prevalence, incidence, mortality and incidence rate ratios.
Journal ArticleDOI
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair M. Younossi,Quentin M. Anstee,Milena Marietti,Timothy Hardy,Timothy Hardy,Linda Henry,Mohammed Eslam,Jacob George,Elisabetta Bugianesi +8 more
TL;DR: The large number of patients with NAFLD with potential for progressive liver disease creates challenges for screening, as the diagnosis of NASH necessitates invasive liver biopsy.
Journal ArticleDOI
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
Zobair M. Younossi,Deirdre B Blissett,Robert Blissett,Linda Henry,Maria Stepanova,Youssef Younossi,Andrei Racila,Sharon A. Hunt,Rachel Beckerman +8 more
TL;DR: The analysis quantifies the enormity of the clinical and economic burdens of NAFLD, which will likely increase as the incidence ofNAFLD continues to rise.
Journal ArticleDOI
Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009
Zobair M. Younossi,Zobair M. Younossi,Munkhzul Otgonsuren,Linda Henry,Chapy Venkatesan,Alita Mishra,Madeline Erario,Sharon L. Hunt +7 more
TL;DR: NAFLD is becoming a major cause of HCC in the United States and is associated with shorter survival time, more advanced tumor stage, and lower possibility of receiving a LT.
Journal ArticleDOI
Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis
Jie Li,Jie Li,Biyao Zou,Yee Hui Yeo,Yuemin Feng,Xiaoyu Xie,Dong Hyun Lee,Hideki Fujii,Yuankai Wu,Yuankai Wu,Leslie Y. Kam,Fanpu Ji,Fanpu Ji,Xiaohe Li,Nicholas Chien,Mike Wei,Eiichi Ogawa,Eiichi Ogawa,Changqing Zhao,Xia Wu,Xia Wu,Christopher D Stave,Linda Henry,Scott D. Barnett,Hirokazu Takahashi,Norihiro Furusyo,Yuichiro Eguchi,Yao-Chun Hsu,Teng-Yu Lee,Wanhua Ren,Chengyong Qin,Dae Won Jun,Hidenori Toyoda,Vincent Wai-Sun Wong,Ramsey Cheung,Ramsey Cheung,Qiang Zhu,Mindie H. Nguyen +37 more
TL;DR: NAFLD prevalence in Asia is increasing and is associated with poor outcomes including hepatocellular carcinoma and death, especially in high-risk groups, such as older obese men, and targeted public health strategies must be developed in Asia.